NEW YORK (360Dx) – Roche Diagnostics said last week that in launching a bleeding risk test it has made important strides that will benefit patients at risk of stroke who need to decide whether to take oral anticoagulants for atrial fibrillation.
360Dx Premium gives you: ✔ Full site access ✔ Interest-based email alerts ✔ Access to archives
Never miss another important industry story.
Try 360Dx Premium now.
You may already have institutional access!
Check if I qualify.
Already a 360Dx or GenomeWeb Premium member?Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.